PURPOSE: To investigate the effect of glucagon on the timing and degre
e of hepatic enhancement at computed tomography. MATERIALS AND METHODS
: Each of 11 dogs underwent injection of contrast material at two unip
hasic rates (0.5 mL/sec and 1.5 mL/sec) with and without previous intr
avenous administation of 0.5 mg of glucagon. Scans were obtained at a
single intrahepatic level every 3.5 seconds for 120-160 seconds. Atten
uation values in the liver, aorta, portal vein, and inferior vena cava
(IVC) were measured. RESULTS: Glucagon administration was associated
with greater hepatic enhancement throughout the study: Peak hepatic en
hancement was greater at contrast injection rates of 0.5 mL/sec (P = .
021) and 1.5 mL/sec (P = .0001). Peak hepatic enhancement also occurre
d earlier during the glucagon runs. Portal vein enhancement was greate
r during the glucagon runs at an injection rate of 1.5 mL/sec (P = .03
2). IVC enhancement was greater during the nonglucagon runs at 0.5 mL/
sec (P = .013) and at 1.5 mL/sec (P = .005). CONCLUSION: Intravenous a
dministration of glucagon before contrast material injection produces
greater and more rapid hepatic enhancement in a canine model.